Investor Presentation October 2017 2017 MRI INTERVENTIONS, INC. | 1 Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking

Presentation October 2017 2017 MRI INTERVENTIONS, INC. | 1

Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth

and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding

the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates

or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks

may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements.

Particular uncertainties and risks include those relating to: the Company's ability to obtain additional financing; estimates

regarding the sufficiency of the Company's cash resources; future revenues from sales of the Company's ClearPoint

System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's

ClearPoint System products. More detailed information on these and additional factors that could affect the Company's actual

results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year

ended December 31, 2016, which has been filed with the Securities and Exchange Commission, and our most recently filed Quarterly

Report on Form 10-Q for the quarter ended June 30, 2017, which will be filed with the Securities and Exchange Commission on or

before August 15, 2017. 2017 MRI INTERVENTIONS, INC. | 2

MRIC: The Platform Company for MRI-Guided Therapies MRI Interventions: Leader in the Delivery of MRI-Guided Therapies Primary

Innovator in the Field, grown out of the Advanced MR department at Johns Hopkins Extensive Intellectual Property position: 70+

issued US patents, 45 international Proven track record for conceiving, developing, commercializing and securing clinical adoption

for our MRI-guided therapy platform Rapidly Growing Commercial Business; Established the Industry Platform for MRI-guided, Minimally-Invasive

Neurosurgery Strong and growing clinical footprint: 48 hospitals in the US Accelerating adoption, revenue growth: 8 successive

quarters of record procedures Current procedures include DBS electrode placement, laser ablation, biopsy, drug delivery MRIC's

platform integrates with products from multiple companies (med device companies, imaging companies, biotechs) Expanding Platform

into Adjacent Areas to Address Additional Unmet Medical Needs Expanding platform into the stroke market; Joint Development Agmt

with Mayo Clinic Expanding our capabilities, adding novel ultrasound ablation technology via Co-Dev Agmt with Acoustic MedSystems;

initial market is pancreatic cancer Leveraging our existing platform, install base and technologies to enable a rapid, cost-effective

path to additional markets 2017 MRI INTERVENTIONS, INC. | 3

Why MRI-Guided Therapies? Image-guided Therapeutic Procedures Have Become a Mainstay in U.S. Healthcare 1.2 Million Arthroscopic

Procedures 1.5 million Fluoroscopic Procedures 4.0 Million Laparoscopic Procedures MRI Guided Therapeutic Procedures are the Next

Step in this Trend Unique capabilities that no other imaging modality can provide High resolution, three-dimensional, continuous,

no radiation MRI-Guided Procedures are Uniquely Positioned to Address Significant Unmet Medical Needs Functional neurological

diseases (e.g., Parkinson's disease, Epilepsy) Untreatable hemorrhagic stroke (e.g., intracerebral hemorrhage) Certain cancers

(e.g., brain, pancreas) 2017 MRI INTERVENTIONS, INC. | 4

Our MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Products from: Medtronic St. Jude

Medical NeuroPace Place Laser Ablation Probes from: Medtronic-Visualase Monteris Medical Deliver Drugs and Biologics from: Voyager

Medicenna Oxford Biomedica International Stem Cell Corporation MRIC Platform Runs on All Major Scanners: Siemens GE Philips IMRIS

2017 MRI INTERVENTIONS, INC. | 5

Broad and Growing User Base of Leading Neurosurgeons ClearPoint Is Installed in 50 Top US Hospitals

and Growing UC San Francisco San Francisco VA Univ of Michigan Stanford Univ Brigham & Women's UCSF Benioff Childrens

Boston Children's USC Yale Univ UC San Diego Univ of Pitt Med Center Univ of Colo Memorial Sloan Kettering Univ of Utah

Hackensack Univ Med Center Univ of Arizona Nat. Institutes of Health Cook Children's Nat Children's Hospital MD Anderson

Children's Hosp of Philadelphia Methodist Hosp Univ of Virginia Texas Children's Hosp Emory University Riverside Carillion

Nationwide Children's Duke University Children's Mercy Children's of Alabama Kansas Univ Med Center CHOA Scottish

Rite Univ of Wisconsin Willis Knighton Spectrum Health Mayo Clinic Jacksonville Ohio State Univ Miami Children's Univ of

Cincinnati Strong Commercial Sales and Clinical Support Teams in Place 2017 MRI INTERVENTIONS, INC. | 6

Foundation of Our Platform: ClearPoint Neuro Navigation System 2017 MRI INTERVENTIONS, INC. | 7

Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed "Blind" Conventional Stereotactic

Procedure ClearPoint Neuro Procedure No real time images images from earlier in the day or week 2017 MRI INTERVENTIONS,

ClearPoint Neuro Navigation System: MRI-Guided NeuroSurgical Platform ClearPoint Components: Capital Sale Recurring

Revenue Reusable Hardware Components Integrated Software Single-Use, Disposable Components Emory University Hospital Univ.

of California San Francisco Univ. of Pittsburgh Medical Center Medical Center 2017 MRI INTERVENTIONS, INC. | 9

Details on Our ClearPoint Neuronavigation System Platform ClearPoint Procedure Overview: ClearPoint Video ClearPoint Video

Entry and Trajectory Alignment and Insertion 2017 MRI INTERVENTIONS, INC. | 10

Multiple Clinical Applications for Our ClearPoint System Platform Electrode Placement and Laser Ablation Drug Delivery

Significant Unmet Medical Parkinson's disease, Epilepsy, Brain Tumor, Dystonia Enabling Multiple Therapies from Multiple

Companies: Electrode Placement: Medtronic, St. Jude, Neuropace Laser Ablation: MDT/Visualase, Monteris Drug Delivery: Voyager,

Medicenna, Oxford Biomedica, Int'l Stem Cell (1) Laser Ablation - MR Thermometry is an MRI-based functionality available

on most MR scanner platforms and it is a feature built into products from several third party vendors. The ClearPoint system enables

MRI-guided procedures and allows physicians to use this inherent MR capability during a procedure. (2) Drug Delivery - The SmartFlow

cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the

ventricles during intracranial procedures. Delivery of other therapeutic agents, and delivery of agents to other areas of the

brain, using the SmartFlow cannula is investigational. 2017 MRI INTERVENTIONS, INC. | 11

Strong Business Model for Our Core MRI-Guided Navigation Platform ClearPoint Hardware/Software: $100,000 - $150,000 ASP

ClearPoint Disposables: ~$7,500 ASP per procedure with strong margins Recurring revenue from the sale of disposables Procedures

covered by existing inpatient DRG reimbursement codes Same razor/razorblade model applies to future product sales 2017

MRI INTERVENTIONS, INC. | 12

ClearPoint Neurosurgical Procedure Growth 800 Procedures 650-700 CAGR, 2013 2016: 46% 700 600 Q1,

2017: 146 500 Procedures 400 Q2, 2017: 162 Procedures 300 Nine quarters in a 200 row of procedure 100 growth 0 2013 2014 2015

2016 2017 Outlook 2017 MRI INTERVENTIONS, INC. | 13

Expanding Our Platform: New Procedural Applications 2017 MRI INTERVENTIONS, INC. | 14

Expanding MRIC's MRI-Guided Therapy Platform Benefits Larger Patient Populations First, MRIC established the

Capability of the Platform Began with Electrode Placement (DBS) Parkinson's disease, dystonia Expanded to Biopsy

Brain Tumor Expanded to Laser Ablation Probe Placement Epilepsy and Brain Tumor Expanded to Drug Delivery Parkinson's Disease

and Brain Tumor now, Expanding the Reach of the MRI-Guided Platform Expanding Adding Novel Ablation Technology to Platform

Initial focus in Pancreatic Cancer 2017 MRI INTERVENTIONS, INC. | 15

Expanding into the Stroke Market Leveraging Existing Capabilities and Install Base Expanding the Reach of the MRIC Platform

into the Stroke Market Joint Development Agreement with Mayo Clinic Dr. Bernard Bendok, Chair of Neurosurgery, Mayo Arizona

Large Stroke Market 5th leading cause of death in US Leading cause of permanent disability Affects 800,000 people in the

US every year Initial Stroke Product (ClearAway ) Targets Intracerebral Hemorrhage (ICH) Only major stroke subtype w/o

clearly effective therapy major unmet medical need Affects 80,000 to 100,000 people in the US each year MRIC market opportunity

is 12,000 to 15,000 cases/year 2017 MRI INTERVENTIONS, INC. | 16

Our MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke Current Approaches for Hemorrhage Removal and Decompression are

Inadequate: Open craniotomy provides visibility but is highly invasive, destroys brain tissue Minimally Invasive approach

has very limited ability to quantify volume reduction of the hemorrhage or monitor subsequent bleeds Our Unique ClearAway MRI-Guided

Therapy Approach to ICH Detailed, continuous, high resolution, 3 dimensional visibility Minimally invasive approach Expected

Path to Market Builds directly on our ClearPoint Platform ClearPoint software and hardware; SmartFrame Hemorrhage aspiration

components Potential 510(k) regulatory path Projected market introduction as soon as 12-18 months U.S. Market Opportunity = $72

million to $90 million 95% of Our Existing ClearPoint Adult Sites Have a Stroke Program! 2017 MRI INTERVENTIONS,

Expanding our Platform with a Novel Ablation Technology Co-Development Agreement Will Add Additional Capabilities License

and Co-Development Agreement with Acoustic MedSystems (AMS) Leading developer of ultrasound ablation technologies and systems

Base technology has 510k clearance Initial license areas: WW Excl. for Pancreatic Cancer, Excl. Option for Brain Applications

AMS Ultrasound Technology Provides Unique Capabilities Directional Ablation over Other Ablative Energy Sources

Precision ablation over small and large areas Directional and depth control "Protected Zone" between transducer

and ablated tissue AMS Ultrasound Technology Works with MRI Interventions' Technology MRI-friendly components Enhanced

by real-time, MRI-guidance Can incorporate real-time MRI-thermometry 2017 MRI INTERVENTIONS, INC. | 18

Co-Development Focused First on Pancreatic Cancer Market Pancreatic Cancer Market Major Unmet Medical Need 50,000 patients

in US diagnosed annually 10,000 to 15,000 cases annually are localized, non-metastatic tumors, but untreatable because of the

tumor location Our Therapeutic Approach Targets Untreatable Tumors pancreas Vascular access to get near the tumor Apply

ultrasound energy to ablate the tumor Destroy the tumor Preserve the vessel Expected Path to Market Begin limited human

use of existing AMS products in September Projected market introduction of integrated pancreatic cancer product as soon as 18

- 24 months Potential 510(k) regulatory path U.S. Market Opportunity = $50 million to $75 million 2017 MRI INTERVENTIONS,

Strong Pipeline of New Products to Add to our Existing Products Leveraging our MRI-Guided Therapy Platform Projected